Amlodipine/Fimasartan/Hydrochlorothiazide

氨氯地平/非马沙坦/氢氯噻嗪

Report date: 2022/03/08 16:47:00

Base Information

Drug NameAmlodipine/Fimasartan/Hydrochlorothiazide
Drug Alias NameHydrochlorothiazide/Fimasartan/Amlodipine非马沙坦/氨氯地平/氢氯噻嗪非马沙坦/氢氯噻嗪/氨氯地平Hydrochlorothiazide/Amlodipine/Fimasartan氨氯地平/氢氯噻嗪/非马沙坦 +[12] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsThiazide-sensitive sodium-chloride cotransporter inhibitorsVoltage-gated calcium channel blockers
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1Voltage-gated calcium channel
Therapy Area/IndicationsHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes HydrochlorothiazideFimasartan Potassium TrihydrateAmlodipine Besylate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoryung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBoryung Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A